CompletedNot Applicable

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

United Kingdom5,225 participantsStarted 2010-06

Plain-language summary

A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Patient already taking the drug in question (clopidogrel or ticagrelor) prior to the ACS event
✕. Patients under 18 years of age
✕. Patients in whom the drug is stopped during the same hospital admission due to clinical judgement dictating that it is no longer indicated (this does not apply to patients in whom a bleeding event is the precipitant for stopping the drug)

The incidence of major bleeding defined by both BARC (3-5) and PLATO definitions

Timeframe: 12 months from treatment starting

NCT IDNCT02484924

SponsorLiverpool University Hospitals NHS Foundation Trust

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2016-06